Latest News and Press Releases

Solengepras is a potentially first-in-class, oral, non-dopaminergic investigational therapy in development for Parkinson’s diseaseARISE will evaluate the efficacy of solengepras as an adjunctive...

CVN293 was generally well-tolerated in healthy volunteers for up to 14-days of continuous dosingDose-dependent exposure was observed with evidence of robust brain penetrationData supports potential...

BOSTON, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative, psychiatric,...

BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative, psychiatric,...

BOSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative, psychiatric...

BOSTON, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, announced that Craig Thompson, chief...

BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Cerevance, a leading clinical-stage biopharmaceutical company focused on developing precision novel therapeutics for central nervous system (CNS) diseases,...

BOSTON, June 18, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, will deliver a poster presentation at the...

BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, announced that Craig Thompson, chief...

BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, will present an oral presentation at the...